

Bladder cancer (BC) can be a debilitating disease and is in the top ten world-wide cancer incidence. It can be considered one of the most expensive cancers to treat per patient and this is in the face of low research funding rates. For decades and until recently, little progress was made in the advancement of BC treatment. In this special compendium, there are six sections related to BC, and this collection represents reports from world experts in the field of BC. No doubt this will be an excellent and added resource as we look to improve the quality of care and health and ultimately survival of BC patients. This often “ignored” and less researched malignancy has been ready for advances and new discoveries for some time. This issue addresses NMIBC (non-muscle invasive) and MIBC (muscle invasive) and debates and illustrates differences in surgical approaches along with perioperative chemotherapy/immunotherapy. With the utilization of molecular biology and findings of genetic alterations, a more personalized or precision medicine concept is taking hold in BC. Those that research and treat BC welcome the novel approaches and often debated topics that this book so adequately addresses.



R. Jeffrey Karnes, MD, FACS
Professor of Urology,
Mayo Clinic, Rochester, MN, USA;
Regional Chair,
Rochester, MN, USA